Marshall Wace’s Pliant Therapeutics PLRX Stock Holding History

Marshall Wace’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.25M	Sell	995,973 -84,155	-8%	-$106K	﹤0.01%	2023
2025 Q4	$1.32M	Buy	1,080,128 +780,667	+261%	+$1.17M	﹤0.01%	1791
2025 Q3	$443K	Buy	+299,461	New	+$457K	﹤0.01%	2275
2025 Q2	–	Sell	-208,532	Closed	-$282K	–	3054
2025 Q1	$282K	Buy	208,532 +154,652	+287%	+$939K	﹤0.01%	2291
2024 Q4	$710K	Buy	+53,880	New	+$736K	﹤0.01%	1891
2024 Q2	–	Sell	-130,935	Closed	-$1.95M	–	2863
2024 Q1	$1.95M	Buy	+130,935	New	+$2.16M	﹤0.01%	1375
2023 Q4	–	Sell	-73,921	Closed	-$1.28M	–	2509
2023 Q3	$1.28M	Buy	+73,921	New	+$1.28M	﹤0.01%	1410
2023 Q2	–	Sell	-37,354	Closed	-$994K	–	2874
2023 Q1	$994K	Sell	37,354 -28,466	-43%	-$810K	﹤0.01%	1812
2022 Q4	$1.27M	Buy	+65,820	New	+$1.38M	﹤0.01%	1975
2022 Q3	–	Sell	-46,414	Closed	-$371K	–	3696
2022 Q2	$371K	Buy	+46,414	New	+$297K	﹤0.01%	2942

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Marshall Wace's PLRX Position: Q1 2026 in Review

Marshall Wace reduced its Pliant Therapeutics (PLRX) stake by 7.8% in Q1 2026, selling an estimated $106K and leaving 995,973 shares worth $1.25M. The position accounts for ﹤0.01% of the portfolio, ranked #2023.

Marshall Wace first reported a position in PLRX in Q2 2022 and has held it in 10 quarters since. The position peaked at $1.95M in Q1 2024. 91 funds tracked by Wall St. Rank hold PLRX as of Q1 2026.

Marshall Wace held 995,973 shares of Pliant Therapeutics worth $1.25M as of Q1 2026.
Marshall Wace sold 84,155 Pliant Therapeutics shares in Q1 2026, an estimated $106K.
Pliant Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2023 holding.
Marshall Wace first reported a position in Pliant Therapeutics in Q2 2022 and has held it in 10 quarters since.
Marshall Wace's Pliant Therapeutics position peaked at $1.95M in Q1 2024.
91 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.